ingest cdrApp 2018-06-13T15:50:11.162Z 51cd2fe2-3fd7-401f-a923-a97bc3db68a2 modifyDatastreamByValue RELS-EXT fedoraAdmin 2018-06-13T16:17:34.645Z Setting exclusive relation addDatastream MD_TECHNICAL fedoraAdmin 2018-06-13T16:17:35.287Z Adding technical metadata derived by FITS addDatastream MD_FULL_TEXT fedoraAdmin 2018-06-13T16:17:47.638Z Adding full text metadata extracted by Apache Tika modifyDatastreamByValue RELS-EXT fedoraAdmin 2018-06-13T16:17:59.111Z Setting exclusive relation modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-07-16T20:56:06.861Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-07-18T16:31:14.643Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-08-22T15:10:43.605Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-09-28T17:55:53.318Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2018-10-12T16:50:25.994Z modifyDatastreamByValue MD_DESCRIPTIVE cdrApp 2019-03-22T20:10:34.072Z Sarah Willis Author Department of Epidemiology Gillings School of Global Public Health Chronic hepatitis C and HIV treatment outcomes among women who initiate antiretroviral therapy One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. Spring 2018 2018 Epidemiology antiretroviral therapy, depression, Hepatitis C virus, HIV eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Epidemiology Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text Sarah Willis Author Department of Epidemiology Gillings School of Global Public Health Chronic hepatitis C and HIV treatment outcomes among women who initiate antiretroviral therapy One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. Spring 2018 2018 Epidemiology antiretroviral therapy, depression, Hepatitis C virus, HIV eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Epidemiology Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text Sarah Willis Author Department of Epidemiology Gillings School of Global Public Health Chronic hepatitis C and HIV treatment outcomes among women who initiate antiretroviral therapy One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. Spring 2018 2018 Epidemiology antiretroviral therapy, depression, Hepatitis C virus, HIV eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Epidemiology Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text Sarah Willis Author Department of Epidemiology Gillings School of Global Public Health Chronic hepatitis C and HIV treatment outcomes among women who initiate antiretroviral therapy One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. Spring 2018 2018 Epidemiology antiretroviral therapy, depression, Hepatitis C virus, HIV eng Doctor of Philosophy Dissertation Epidemiology Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution Sarah Willis Creator Department of Epidemiology Gillings School of Global Public Health Chronic hepatitis C and HIV treatment outcomes among women who initiate antiretroviral therapy One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. Epidemiology antiretroviral therapy; depression; Hepatitis C virus; HIV eng Doctor of Philosophy Dissertation Epidemiology Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text University of North Carolina at Chapel Hill Degree granting institution 2018 2018-05 Sarah Willis Author Department of Epidemiology Gillings School of Global Public Health Chronic hepatitis C and HIV treatment outcomes among women who initiate antiretroviral therapy One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. Spring 2018 2018 Epidemiology antiretroviral therapy, depression, Hepatitis C virus, HIV eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Epidemiology Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text Sarah Willis Creator Department of Epidemiology Gillings School of Global Public Health One in four persons living with HIV is coinfected with chronic hepatitis C virus (HCV). Biological interaction between HIV and HCV, and behaviors such as decreased antiretroviral therapy (ART) adherence and drug use, may negatively impact HIV treatment outcomes among persons with HIV/HCV-coinfection. Yet, previous research assessing the effect of HCV on HIV treatment outcomes produced inconsistent results. Evidence regarding the effect of HCV on HIV treatment outcomes is also lacking among women. Therefore, we estimated the effect of chronic HCV on HIV suppression and the effects of chronic HCV and depression on AIDS diagnosis or death among women who initiated ART while enrolled in the Women’s Interagency HIV Study (WIHS). We estimated the effect of chronic HCV on HIV suppression by comparing the proportion of study visits with detectable HIV RNA between women with and without chronic HCV. Among 441 women who initiated ART in 2000 or after, 114 (26%) had chronic HCV. Overall, the risk of having a visit with detectable HIV RNA was similar among women with and without chronic HCV (risk ratio (RR) 1.19; 95% confidence interval (CI) 0.72, 1.95)). However, six months after ART initiation, the proportion of visits with detectable HIV RNA among women with chronic HCV was 1.88 (95% CI 1.41, 2.51) times that among women without chronic HCV, at two years the ratio was 1.60 (95% CI 1.17, 2.19), and by six years there was no difference (RR 1.03; 95% CI 0.60, 1.79). When assessing the effects of chronic HCV and depression on AIDS diagnosis or death among 957 women who initiated ART between 1995 and 2015, 200 women (21%) had chronic HCV. The incidence rates of AIDS diagnosis or death were 7.12 and 3.80 per 100 person-years for women with and without chronic HCV, respectively. Compared to women without chronic HCV and depression, the hazard ratio (HR) for AIDS diagnosis or death was 2.19 (95% CI 1.56, 3.07) for HCV-uninfected women with depression, 1.65 (95% CI 0.90, 3.01) for HCV-infected women without depression, and 3.02 (95% CI 1.49, 6.15) for HCV-infected women with depression. 2018-05 2018 Epidemiology antiretroviral therapy; depression; Hepatitis C virus; HIV eng Doctor of Philosophy Dissertation University of North Carolina at Chapel Hill Graduate School Degree granting institution Stephen Cole Thesis advisor Adaora Adimora Thesis advisor Andrew Edmonds Thesis advisor Christopher Hurt Thesis advisor Daniel Westreich Thesis advisor text Willis_unc_0153D_17627.pdf uuid:8ac08903-c591-47a5-ae15-c9818b4da283 2020-06-13T00:00:00 2018-04-19T00:47:32Z proquest application/pdf 2242732